Background*

Ms. Julie H. McHugh has been a Director of EPIRUS Biopharmaceuticals, Inc., since July 18, 2014, Ironwood Pharmaceuticals, Inc., since February 12, 2014 and Trevena, Inc. since July 1, 2014. Ms. McHugh serves as Director of Xellia Pharmaceuticals ApS. She serves as a Director of Xellia Pharmaceuticals, Inc., Xellia Pharmaceuticals AS and The Pennsylvania Biotechnology Association. She has been a Director of Penwest Pharmaceuticals Co. since September 20, 2010. She served ... as the Chief Operating Officer of Endo International plc (alternate names, Endo Health Solutions and Endo Pharmaceuticals Holdings Inc.) from March 13, 2010 to May 29, 2013 and its subsidiary, Endo Pharmaceuticals Solutions Inc., from March 2010 to May 29, 2013. Ms. McHugh was responsible for both the specialty pharmaceuticals and generic pharmaceuticals businesses. She has over 28 years of experience in the drug development industry. She served as the Chief Executive Officer and President of Nora Therapeutics, Inc. Prior to Nora Therapeutics, she served as Company Group Chairman for Worldwide Virology Business Unit at Johnson & Johnson from 2006 to 2008, where she led a growing area of its pharmaceutical business including the global launches of PREZISTA® and INTELENCE® and oversight of a dynamic R&D portfolio including compounds for HIV, Hepatitis C, and Tuberculosis. From 2004 to 2006, she served as President of Centocor, Inc., a J&J subsidiary, and was responsible for the product development and commercialization of REMICADE®, a breakthrough therapeutic for Crohn’s disease, rheumatoid arthritis and several other autoimmune disorders. Previously, Ms. McHugh held marketing positions of increasing scope and accountability at Astra-Merck, Rhone-Poulenc Rorer (Sanofi Aventis) and SmithKline (GlaxoSmithKline). She served as the Chairman of The Pennsylvania Biotechnology Association since 2009. She served as a Director at Biotechnology Industry Organization since July 2011. She served as a Director of ViroPharma Inc., from January 3, 2012 to January 24, 2014 and Nora Therapeutics, Inc. She serves on the Board of Visitors for the Smeal College of Business of the Pennsylvania State University and Board of Directors for the Nathaniel Adamczyk Foundation. Ms. McHugh holds a Bachelor of Science degree in Finance from Pennsylvania State University and a Masters of Business Administration in International Management from St. Joseph's University.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.